Dual-pathway biology at a lower starting scale.
A lower-dose compounded tirzepatide and B12 prescription that keeps dual-receptor biology inside clinician-led care.
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
About 10 minutes. No charge unless your clinician approves.
Two incretin pathways, with B12 in the formulation.
Metabolic treatment sometimes requires a formulation tailored to the patient rather than a standard finished product, and the reason for compounding belongs to the clinical case, not to a preference selected at checkout. This compounded preparation pairs tirzepatide with vitamin B12 for exactly that situation: it is prescribed only where a licensed clinician documents that the combination is clinically appropriate for you.
Tirzepatide activates GIP and GLP-1 receptors, affecting appetite, gastric emptying, glucose-dependent insulin secretion, and glucagon signaling. Vitamin B12 is required for normal neurologic function, red blood cell formation, and DNA synthesis. Evidence from FDA-approved tirzepatide finished drug products does not establish that adding B12 improves tirzepatide efficacy or tolerability, or that this compounded preparation produces equivalent results.
The differentiation is dual-receptor biology at a lower starting scale, with B12 included in the formula. If the clinical plan later calls for standard titration, the same care relationship can make that decision without forcing the patient to start over.
Read the evidence →For the case that needs more than a standard template.
The Individualized Case
A standard finished product does not answer a documented prescribing need. You want the formulation decision made from your medical history rather than from a product menu.
The Prior Incretin Patient
Your past response and tolerability give your clinician real information to work with. The next prescription should use that information, not ignore it.
The Holding Pattern
During care, a provider may determine that a reduced-dose phase fits the patient's current clinical picture. The dose is set by the provider and is not an entry point selected at signup.
This compounded tirzepatide and B12 preparation is not FDA approved. Evidence does not establish that B12 improves tirzepatide efficacy or tolerability, or that this compounded preparation is equivalent to an FDA-approved tirzepatide product.
This might not be the right fit if:
- You have a personal or family history of medullary thyroid carcinoma or MEN 2.
- You are pregnant, planning pregnancy, or breastfeeding.
- You have a history of pancreatitis that has not been reviewed with your clinician.
- You have severe gastroparesis or another severe gastrointestinal motility disorder.
- You have a known hypersensitivity to tirzepatide, vitamin B12, cobalt, or another component of the preparation.
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Tirzepatide + B12 Microdose, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Licensed provider review of your history, medications, goals, and prior incretin response
- Documented clinical rationale for the compounded formulation
- Individual prescription prepared by a licensed 503A pharmacy if approved
- Treatment changes remain clinician-directed rather than self-selected
- Ongoing follow-up connected to the broader metabolic plan
Alternate dosage forms are compounded only where a licensed clinician documents a patient-specific clinical need that a commercially available product cannot meet. They are not interchangeable with, and are not substitutes for, FDA-approved products. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Metabolic.
Semaglutide
A clinician on the other end of every dose.
Compounded semaglutide injection with clinician review, pharmacy fulfillment, shipping, and follow-up inside one care model. (Contains semaglutide.)
Tirzepatide
Two incretin pathways. One physician watching both.
Compounded tirzepatide injection built around dual GIP and GLP-1 receptor biology with clinician-directed dosing and follow-up. (Contains tirzepatide.)
Semaglutide + B12 Microdose
A lower-dose path with B12 built in.
A lower-dose compounded semaglutide and B12 prescription for clinician-guided metabolic care at a different starting scale. (Contains semaglutide and vitamin B12.)
What the research shows
One peptide activates both incretin receptors, with a half-life of about five days.
The detail
Tirzepatide is a single peptide that binds to and activates both the GIP receptor and the GLP-1 receptor, the targets of the two native incretin hormones, and it carries a C20 fatty diacid that enables albumin binding and an elimination half-life of approximately five days, which labeling describes as what enables once-weekly dosing of the approved product.1
Tirzepatide raises insulin, lowers glucagon and delays gastric emptying most after the first dose.
The detail
Approved tirzepatide labeling states that the molecule enhances insulin secretion and reduces glucagon, both in a glucose-dependent manner, and that it delays gastric emptying, an effect largest after the first dose that diminishes over time.1
Labeling ties GLP-1 to appetite; the GIP contribution rests on nonclinical studies.
The detail
Labeling further describes GLP-1 as a physiological regulator of appetite and caloric intake, notes that GIP and GLP-1 receptors are found in areas of the brain involved in appetite regulation, and attributes the further contribution of GIP to food-intake regulation to nonclinical studies.2
Vitamin B12 has no incretin activity; it is an enzyme cofactor.
The detail
Vitamin B12 has no incretin receptor activity. It functions as a cofactor for two enzymes, methionine synthase and L-methylmalonyl-CoA mutase, and is required for red blood cell formation, DNA synthesis, and the development, myelination and function of the central nervous system.3
Injected vitamin B12 bypasses the intrinsic factor that gut absorption depends on.
The detail
Injectable cyanocobalamin labeling states that vitamin B12 is rapidly absorbed from intramuscular and subcutaneous sites of injection, whereas gastrointestinal absorption of vitamin B12 depends on sufficient intrinsic factor, which is the pharmacologic reason an injectable route is used at all.4
What it does not show
A compounded preparation is not an FDA-approved drug product.
The detail
A compounded preparation is not an FDA-approved drug product, and FDA does not verify the safety, effectiveness or quality of a compounded drug before it is marketed.5
This block describes mechanism only and reports no trial result.
The detail
Every mechanism statement above is drawn from the clinical pharmacology section of approved labeling and from equivalent pharmacology sources, sections that are separate from the clinical studies section of the same labeling. This block deliberately describes how each ingredient works and does not report what any trial measured.1
Dual agonism is a binding property, not a claim of superior results.
The detail
Dual agonism means one molecule occupies two incretin receptors, a property characterized in vitro through receptor-occupancy analysis and cell signalling assays. It is a statement about receptor binding rather than a claim of results superior to agonism at the GLP-1 receptor alone.6
Vitamin B12 has no established effect on body weight.
The detail
Injectable vitamin B12 labeling gives treatment of vitamin B12 deficiency states as its indication and describes no effect of vitamin B12 on body weight. Adding vitamin B12 to a preparation has no established effect on weight.4
No source here describes the compounded tirzepatide and vitamin B12 preparation itself.
The detail
The labeling relied on above describes an approved single-ingredient tirzepatide product, including its pharmacokinetics and dosing interval. It does not describe a compounded tirzepatide and vitamin B12 preparation, and no source cited here characterizes the exposure produced by such a preparation.1
- FDA-approved tirzepatide injection prescribing information, sections…DailyMed
- FDA-approved tirzepatide injection prescribing information, section…DailyMed
- National Institutes of Health, Office of Dietary Supplements. Vitamin B12: fact sheet for health professionals.Source
- FDA-approved cyanocobalamin injection, USP prescribing information…DailyMed
- FDA, Compounding and the FDA: Questions and Answers.FDA
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor… JCI Insight. 2020. In vitro receptor pharmacology.
FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown.
Do not use if you have
- A personal or family history of medullary thyroid carcinoma or MEN 2
- Sensitivity to cobalt or vitamin B12
Serious risks
- Pancreatitis
- Gallbladder disease
- Severe gastrointestinal reactions
- Kidney injury related to dehydration
- Hypoglycemia when tirzepatide is used with insulin or insulin secretagogues
- Serious hypersensitivity reactions have been reported after parenteral administration of injected vitamin B12
Commonly reported
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
- Indigestion
- Soreness where you inject
Reported effects are mostly gastrointestinal, along with soreness where you inject. The important risks are in tirzepatide labeling. That warning is why pregnancy plans, pancreatitis history, gastrointestinal motility disease, and glucose-lowering medications are reviewed first. Injected vitamin B12 adds its own labeled cautions. Those risks are described for the individual components rather than for this compounded combination, which is one more reason the prescribing decision stays with a clinician.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Vitamin B12 is an essential vitamin involved in normal neurologic function, red blood cell formation, and DNA synthesis. Evidence does not establish that adding B12 makes tirzepatide more effective, improves tolerability, or reproduces the results of FDA-approved tirzepatide finished drug products.
Tirzepatide is the active ingredient in FDA-approved finished drug products, and vitamin B12 is an established vitamin ingredient. This combination is compounded. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.
Randomized trials of FDA-approved tirzepatide finished drug products show substantial weight reduction in studied populations. Those studies did not evaluate this compounded tirzepatide and B12 formulation, so they do not establish equivalent safety, exposure, or results for it.
Tirzepatide commonly causes nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. Important risks include pancreatitis, gallbladder disease, kidney injury related to dehydration, severe gastrointestinal reactions, and hypoglycemia when tirzepatide is used with insulin or insulin secretagogues. FDA-approved tirzepatide products carry a boxed warning about thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. Vitamin B12 can rarely cause hypersensitivity reactions. Your clinician reviews relevant history, pregnancy plans, medications, and glucose-lowering therapy before prescribing.
Any time, before your renewal date. No phone calls required.